Please login to the form below
Sofinnova Partners
This page shows the latest Sofinnova Partners news and features for those working in and with pharma, biotech and healthcare.
Muna raises $73m to advance neurodegenerative disease-focused small molecule pipeline
We are honoured to co-lead this round with Sofinnova Partners, Droia Ventures and LSP Dementia Fund – a tremendous joint effort to bring Muna to the next level,” said Morten Graugaard
Latest news
-
Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs
Ashrafian, a partner at SV Health Investors, which co-led the Series A with Sofinnova Partners.
-
Illumina sets up first ex-US accelerator site in Cambridge
Cambridge is of course also where Illumina was carrying out the DNA sequencing for the UK’s 100, 000 Genomes Project, in collaboration with Genomics England and other partners such as ... Illumina is joining forces with several venture firms for the
-
Daily Brief: Charity criticises NHSE and Vertex over Orkambi access, Sema scores again, NodThera launched
The fundraising was co-led by leading healthcare investors Sofinnova Partners and 5AM Ventures, with Epidarex Capital and F-Prime Capital Partners also taking part.
-
Morning brief: Allergan’s migraine results, Biktarvy approved in Europe and more
Its investors are Andera Partners (via Europe’s largest life sciences fund Biodiscovery V) and new backers, China’s Quan, plus existing investors Sofinnova Partners, IP Group, EMBL and Takeda Ventures.
-
News in brief, July 04, 2007
Sofinnova Partners, a French investment firm, led the Series A round, joined by additional backers Norway-based NeoMed Management and Bostonís MVM Life Science Partners. ... The lead investor was Special Situations Fund, while other investors were Fort
More from news
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest appointments
-
Dr Martin Rothman joins Sofinnova Partners
Rothman brings 40 years of experience along with an international network in the medical field to Sofinnova Partners. ... Rothman said: “I am thrilled to join Sofinnova Partners’ team as venture partner.
-
Kala Pharma appoints Fovea founder Bernard Gilly to board
Prior to his involvement with Fovea, Dr Gilly was a venture partner with Sofinnova Partners from 2000 to 2005.
More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- FDA external report recommends actions to address US opioid crisis
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- The increasing value of rare disease trials
- Wrapping up EAU with a Look at Medscape’s Urology Impact
- MHRA to introduce new UK clinical trials framework
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
- Congress is in session – how companies are boosting their impact and engagement
- AstraZeneca announces major expansion of Canadian research footprint
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
PMHub
Langland
Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
